# Expanded Access of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory ITP

> **NCT03363334** · — · NO_LONGER_AVAILABLE · sponsor: **Rigel Pharmaceuticals**

## Conditions studied

- Immune Thrombocytopenic Purpura

## Interventions

- **DRUG:** Fostamatinib disodium 100 mg
- **DRUG:** Fostamatinib disodium 150 mg

## Key facts

- **NCT ID:** NCT03363334
- **Lead sponsor:** Rigel Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2018-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03363334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03363334, "Expanded Access of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory ITP". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03363334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*